Oh_老虎社区_美港股上老虎

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":601811268,"tweetId":"601811268","gmtCreate":1638507145648,"gmtModify":1638507145724,"author":{"id":4100179725007900,"idStr":"4100179725007900","authorId":4100179725007900,"authorIdStr":"4100179725007900","name":"Cheekyd","avatar":"https://static.tigerbbs.com/05e7c6e8bcef8bb9fade899aca08288b","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":25,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Oh&nbsp;</body></html>","htmlText":"<html><head></head><body>Oh&nbsp;</body></html>","text":"Oh","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/601811268","repostId":1138497635,"repostType":4,"repost":{"id":"1138497635","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638436217,"share":"https://www.laohu8.com/m/news/1138497635?lang=zh_CN&edition=full","pubTime":"2021-12-02 17:10","market":"us","language":"en","title":"Moderna shares dipped more than 2% in premarket trading<blockquote>Moderna股价在盘前交易中下跌超过2%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1138497635","media":"Tiger Newspress","summary":"Moderna shares dipped more than 2% in premarket trading as it could be sued over vaccines as court u","content":"Moderna shares dipped more than&nbsp;2% in premarket trading&nbsp;as&nbsp;it&nbsp;could be sued over vaccines as court upholds Arbutus patents.<blockquote>Moderna股价在盘前交易中下跌超过2%，因为法院支持杨梅专利，该公司可能会因疫苗问题被起诉。</blockquote> <img src=\"https://static.tigerbbs.com/c4b23d228b24ede7e56c373ea5ecd787\" tg-width=\"853\" tg-height=\"622\" width=\"100%\" height=\"auto\"><blockquote></blockquote> Moderna Inc&nbsp;could face a patent infringement lawsuit over its COVID-19 vaccine after a federal appeals court on Wednesday rejected its challenge to patents belonging to Arbutus Biopharma Corp.<blockquote>Moderna Inc可能因其COVID-19疫苗面临专利侵权诉讼，此前联邦上诉法院周三驳回了其对Arbutus Biopharma Corp.专利的质疑。</blockquote> The Federal Circuit U.S. Court of Appeals let stand an administrative panel's findings that Arbutus' patents - which may cover technology used in the vaccines - are valid, as the science involved was not previously known.<blockquote>美国联邦巡回上诉法院维持了行政小组的调查结果，即Arbutus的专利（可能涵盖疫苗中使用的技术）是有效的，因为所涉及的科学此前并不为人所知。</blockquote> Moderna previously said in court filings that it believes Arbutus could bring a lawsuit demanding royalties from its COVID-19 vaccine if the patents were upheld.<blockquote>Moderna此前在法庭文件中表示，如果专利得到维持，它认为Arbutus可能会提起诉讼，要求其COVID-19疫苗支付特许权使用费。</blockquote> The company last month forecast 2021 sales of between $15 billion and $18 billion, and 2022 sales of between $17 billion and $22 billion, for its COVID-19 vaccine.<blockquote>该公司上个月预测其COVID-19疫苗2021年的销售额将在150亿美元至180亿美元之间，2022年的销售额将在170亿美元至220亿美元之间。</blockquote> Jefferies analyst Dennis Ding said an infringement lawsuit was possible, but could drag for years, adding that Arbutus will likely settle for a small royalty.<blockquote>杰富瑞(Jefferies)分析师丹尼斯·丁(Dennis Ding)表示，侵权诉讼是可能的，但可能会持续数年，并补充说，Arbutus可能会满足于收取少量特许权使用费。</blockquote> \"When you're thinking about the revenue opportunity from the vaccine, so just like $10 (billion) to $20 billion annually, a small low-single-digit royalty is immaterial to Moderna,\" he said.<blockquote>“当你考虑疫苗的收入机会时，就像每年100亿至200亿美元一样，少量的低个位数特许权使用费对Moderna来说并不重要，”他说。</blockquote> Both patents in question involve the so-called lipid nanoparticles that enclose the genetic material, known as messenger RNA (mRNA), in the vaccine. The technology could prove useful in developing future mRNA-based vaccines against other illnesses as well.<blockquote>这两项专利都涉及所谓的脂质纳米颗粒，这些纳米颗粒包裹着疫苗中称为信使RNA(mRNA)的遗传物质。该技术也可能有助于开发未来基于mRNA的针对其他疾病的疫苗。</blockquote> Moderna initially challenged the patents before the U.S. Patent Trial and Appeal Board, part of the federal patent office. The board agreed with Moderna that some portions of one of the patents were invalid but otherwise sided with Arbutus, and the Federal Circuit upheld its findings.<blockquote>Moderna最初向联邦专利局下属的美国专利审判和上诉委员会对这些专利提出质疑。委员会同意Moderna的观点，即其中一项专利的某些部分无效，但在其他方面站在Arbutus一边，联邦巡回法院支持其调查结果。</blockquote> The patents are licensed to Genevant Sciences Inc, a company launched in 2018 by Arbutus and Roivant Sciences Ltd. Roivant owns about 80% of Genevant and Arbutus owns the remainder.<blockquote>这些专利被授权给Genevant Sciences Inc，该公司由Arbutus和Roivant Sciences Ltd于2018年成立。Roivant拥有Genevant约80%的股份，Arbutus拥有其余股份。</blockquote> Moderna is also embroiled in a months-long patent conflict over its COVID-19 vaccine with the U.S. National Institutes of Health (NIH).<blockquote>Moderna还卷入了与美国国立卫生研究院(NIH)长达数月的COVID-19疫苗专利冲突。</blockquote> NIH has asserted that three of its scientists helped design the genetic sequence used in Moderna's multibillion-dollar vaccine and should be named on the patent application, a claim the company disagrees with.<blockquote>NIH声称，其三名科学家帮助设计了Moderna价值数十亿美元的疫苗中使用的基因序列，应该在专利申请中命名，但该公司不同意这一说法。</blockquote> The company maintains that the mRNA sequence in the company's vaccine was selected exclusively by Moderna's scientists, and without input of NIH scientists.<blockquote>该公司坚称，该公司疫苗中的mRNA序列完全由Moderna的科学家选择，没有NIH科学家的参与。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna shares dipped more than 2% in premarket trading<blockquote>Moderna股价在盘前交易中下跌超过2%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna shares dipped more than 2% in premarket trading<blockquote>Moderna股价在盘前交易中下跌超过2%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nTiger Newspress \n2021-12-02 17:10\n</div>\n</a>\n</h4>\n</header>\n<article>\nModerna shares dipped more than&nbsp;2% in premarket trading&nbsp;as&nbsp;it&nbsp;could be sued over vaccines as court upholds Arbutus patents.<blockquote>Moderna股价在盘前交易中下跌超过2%，因为法院支持杨梅专利，该公司可能会因疫苗问题被起诉。</blockquote> <img src=\"https://static.tigerbbs.com/c4b23d228b24ede7e56c373ea5ecd787\" tg-width=\"853\" tg-height=\"622\" width=\"100%\" height=\"auto\"><blockquote></blockquote> Moderna Inc&nbsp;could face a patent infringement lawsuit over its COVID-19 vaccine after a federal appeals court on Wednesday rejected its challenge to patents belonging to Arbutus Biopharma Corp.<blockquote>Moderna Inc可能因其COVID-19疫苗面临专利侵权诉讼，此前联邦上诉法院周三驳回了其对Arbutus Biopharma Corp.专利的质疑。</blockquote> The Federal Circuit U.S. Court of Appeals let stand an administrative panel's findings that Arbutus' patents - which may cover technology used in the vaccines - are valid, as the science involved was not previously known.<blockquote>美国联邦巡回上诉法院维持了行政小组的调查结果，即Arbutus的专利（可能涵盖疫苗中使用的技术）是有效的，因为所涉及的科学此前并不为人所知。</blockquote> Moderna previously said in court filings that it believes Arbutus could bring a lawsuit demanding royalties from its COVID-19 vaccine if the patents were upheld.<blockquote>Moderna此前在法庭文件中表示，如果专利得到维持，它认为Arbutus可能会提起诉讼，要求其COVID-19疫苗支付特许权使用费。</blockquote> The company last month forecast 2021 sales of between $15 billion and $18 billion, and 2022 sales of between $17 billion and $22 billion, for its COVID-19 vaccine.<blockquote>该公司上个月预测其COVID-19疫苗2021年的销售额将在150亿美元至180亿美元之间，2022年的销售额将在170亿美元至220亿美元之间。</blockquote> Jefferies analyst Dennis Ding said an infringement lawsuit was possible, but could drag for years, adding that Arbutus will likely settle for a small royalty.<blockquote>杰富瑞(Jefferies)分析师丹尼斯·丁(Dennis Ding)表示，侵权诉讼是可能的，但可能会持续数年，并补充说，Arbutus可能会满足于收取少量特许权使用费。</blockquote> \"When you're thinking about the revenue opportunity from the vaccine, so just like $10 (billion) to $20 billion annually, a small low-single-digit royalty is immaterial to Moderna,\" he said.<blockquote>“当你考虑疫苗的收入机会时，就像每年100亿至200亿美元一样，少量的低个位数特许权使用费对Moderna来说并不重要，”他说。</blockquote> Both patents in question involve the so-called lipid nanoparticles that enclose the genetic material, known as messenger RNA (mRNA), in the vaccine. The technology could prove useful in developing future mRNA-based vaccines against other illnesses as well.<blockquote>这两项专利都涉及所谓的脂质纳米颗粒，这些纳米颗粒包裹着疫苗中称为信使RNA(mRNA)的遗传物质。该技术也可能有助于开发未来基于mRNA的针对其他疾病的疫苗。</blockquote> Moderna initially challenged the patents before the U.S. Patent Trial and Appeal Board, part of the federal patent office. The board agreed with Moderna that some portions of one of the patents were invalid but otherwise sided with Arbutus, and the Federal Circuit upheld its findings.<blockquote>Moderna最初向联邦专利局下属的美国专利审判和上诉委员会对这些专利提出质疑。委员会同意Moderna的观点，即其中一项专利的某些部分无效，但在其他方面站在Arbutus一边，联邦巡回法院支持其调查结果。</blockquote> The patents are licensed to Genevant Sciences Inc, a company launched in 2018 by Arbutus and Roivant Sciences Ltd. Roivant owns about 80% of Genevant and Arbutus owns the remainder.<blockquote>这些专利被授权给Genevant Sciences Inc，该公司由Arbutus和Roivant Sciences Ltd于2018年成立。Roivant拥有Genevant约80%的股份，Arbutus拥有其余股份。</blockquote> Moderna is also embroiled in a months-long patent conflict over its COVID-19 vaccine with the U.S. National Institutes of Health (NIH).<blockquote>Moderna还卷入了与美国国立卫生研究院(NIH)长达数月的COVID-19疫苗专利冲突。</blockquote> NIH has asserted that three of its scientists helped design the genetic sequence used in Moderna's multibillion-dollar vaccine and should be named on the patent application, a claim the company disagrees with.<blockquote>NIH声称，其三名科学家帮助设计了Moderna价值数十亿美元的疫苗中使用的基因序列，应该在专利申请中命名，但该公司不同意这一说法。</blockquote> The company maintains that the mRNA sequence in the company's vaccine was selected exclusively by Moderna's scientists, and without input of NIH scientists.<blockquote>该公司坚称，该公司疫苗中的mRNA序列完全由Moderna的科学家选择，没有NIH科学家的参与。</blockquote>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138497635","content_text":"Moderna shares dipped more than 2% in premarket trading as it could be sued over vaccines as court upholds Arbutus patents.\n\nModerna Inc could face a patent infringement lawsuit over its COVID-19 vaccine after a federal appeals court on Wednesday rejected its challenge to patents belonging to Arbutus Biopharma Corp.\nThe Federal Circuit U.S. Court of Appeals let stand an administrative panel's findings that Arbutus' patents - which may cover technology used in the vaccines - are valid, as the science involved was not previously known.\nModerna previously said in court filings that it believes Arbutus could bring a lawsuit demanding royalties from its COVID-19 vaccine if the patents were upheld.\nThe company last month forecast 2021 sales of between $15 billion and $18 billion, and 2022 sales of between $17 billion and $22 billion, for its COVID-19 vaccine.\nJefferies analyst Dennis Ding said an infringement lawsuit was possible, but could drag for years, adding that Arbutus will likely settle for a small royalty.\n\"When you're thinking about the revenue opportunity from the vaccine, so just like $10 (billion) to $20 billion annually, a small low-single-digit royalty is immaterial to Moderna,\" he said.\nBoth patents in question involve the so-called lipid nanoparticles that enclose the genetic material, known as messenger RNA (mRNA), in the vaccine. The technology could prove useful in developing future mRNA-based vaccines against other illnesses as well.\nModerna initially challenged the patents before the U.S. Patent Trial and Appeal Board, part of the federal patent office. The board agreed with Moderna that some portions of one of the patents were invalid but otherwise sided with Arbutus, and the Federal Circuit upheld its findings.\nThe patents are licensed to Genevant Sciences Inc, a company launched in 2018 by Arbutus and Roivant Sciences Ltd. Roivant owns about 80% of Genevant and Arbutus owns the remainder.\nModerna is also embroiled in a months-long patent conflict over its COVID-19 vaccine with the U.S. National Institutes of Health (NIH).\nNIH has asserted that three of its scientists helped design the genetic sequence used in Moderna's multibillion-dollar vaccine and should be named on the patent application, a claim the company disagrees with.\nThe company maintains that the mRNA sequence in the company's vaccine was selected exclusively by Moderna's scientists, and without input of NIH scientists.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":2563,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/601811268"}